Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.59 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4908677 | 0.82 | F10 (0.61) | F10ABCB11F2ST14PTGS2 | |
| SCHEMBL4903522 | 0.81 | F10 (0.61) | F10ABCB11F2ST14PTGS2 | |
| SCHEMBL8208813 | 0.79 | F10 (0.68) | F10ABCB11F2ST14PTGS2 | |
| SCHEMBL4911161 | 0.79 | F10 (0.58) | F10ABCB11F2ST14PTGS2 | |
| SCHEMBL29531354 | 0.79 | F10 (0.65) | F10ABCB11F2ST14PTGS2 | |
| SCHEMBL1097012 | 0.79 | F10 (0.62) | F10F2 | |
| SCHEMBL1097501 | 0.79 | F10 (0.62) | F10ABCB11F2ST14PTGS2 | |
| SCHEMBL1277570 | 0.78 | F10 (0.61) | F10ABCB11F2ST14PTGS2 | |
| SCHEMBL1096523 | 0.78 | MAPT (0.47) | F10 | |
| SCHEMBL8245873 | 0.78 | F10 (0.61) | F10ABCB11F2ST14PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051578-A1 | SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | DAHMANN GEORG | 2008-02-28 | — | — | US | disclosed |
| US-20080051578-A1 | SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | DAHMANN GEORG | 2008-02-28 | — | — | US | disclosed |
| US-20080051578-A1 | SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | DAHMANN GEORG | 2008-02-28 | — | — | US | disclosed |
| WO-2007025940-A1 | SUBSTITUTED BIARYLS AND THEIR USE AS FACTOR XA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051578-A1 | SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | CYP11B2, CYP3A43, CYP11B1 | F10 2414/4885ABCB11 5/4885F2 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.